Regeneron Pharmaceuticals reported $33.5B in Equity Capital and Reserves for its fiscal quarter ending in September of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -4.58B 1.35B Sep/2026
Agenus USD -199.08M 22.15M Jun/2026
Agios Pharmaceuticals USD 979.34M 46.68M Sep/2026
Alnylam Pharmaceuticals USD 3.6B 2.25B Sep/2026
Amgen USD 14.35B 2.66B Sep/2026
Astellas Pharma JPY 1.98T 39.03B Sep/2026
AstraZeneca USD 51.73B 1.43B Sep/2026
Biogen USD 19.04B 194.3M Sep/2026
BioMarin Pharmaceutical USD 6.26B 65.66M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Eli Lilly USD 40.27B 6.39B Sep/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
GlaxoSmithKline GBP 18.75B 1.11B Sep/2026
Incyte USD 5.64B 701.49M Sep/2026
Ionis Pharmaceuticals USD 393.64M 46.1M Sep/2026
J&J USD 81.53B 3.44B Sep/2026
Kyowa Hakko Kirin JPY 908.54B 7.62B Sep/2026
Merck USD 44.89B 2.96B Sep/2026
Moderna USD 6.84B 76M Sep/2026
Neurocrine Biosciences USD 3.88B 185.1M Sep/2026
Novartis USD 37.23B 4.72B Sep/2026
Novartis USD 37.56B 1.36B Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.58B Jun/2026
Sarepta Therapeutics USD 1.53B 1.06M Sep/2026
Teva Pharmaceutical Industries USD 7.98B 226M Sep/2026
Ultragenyx Pharmaceutical USD -376M 85M Sep/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Vertex Pharmaceuticals USD 20.91B 659.5M Sep/2026